103 related articles for article (PubMed ID: 20405530)
1. HIV infection in IVDUs decreases with expanded HIV treatment coverage.
AIDS Patient Care STDS; 2010 Apr; 24(4):266. PubMed ID: 20405530
[No Abstract] [Full Text] [Related]
2. Is antiretroviral therapy modifying the HIV epidemic?
Grulich AE; Wilson DP
Lancet; 2010 Nov; 376(9755):1824; author reply 1825. PubMed ID: 21111902
[No Abstract] [Full Text] [Related]
3. Sexual risk behavior in HIV-infected injection drug users.
Battegay M; Bucher HC; Vernazza P
Clin Infect Dis; 2004 Apr; 38(8):1175-7. PubMed ID: 15095225
[No Abstract] [Full Text] [Related]
4. Impact of HAART and injection drug use on life expectancy of two HIV-positive cohorts in British Columbia.
Lloyd-Smith E; Brodkin E; Wood E; Kerr T; Tyndall MW; Montaner JS; Hogg RS
AIDS; 2006 Feb; 20(3):445-50. PubMed ID: 16439879
[TBL] [Abstract][Full Text] [Related]
5. Prevention. HAART expansion leads to drop in new infections among infection drug users.
AIDS Policy Law; 2010 Mar; 25(4):1. PubMed ID: 20480629
[No Abstract] [Full Text] [Related]
6. Neuropsychological impairment among asymptomatic HIV-positive former intravenous drug users.
Rodríguez Salgado D; Rodríguez Alvarez M; Seoane Pesqueira G
Cogn Behav Neurol; 2006 Jun; 19(2):95-104. PubMed ID: 16783132
[TBL] [Abstract][Full Text] [Related]
7. Treating people to prevent the spread of HIV.
McEnery R
IAVI Rep; 2008; 12(4):16. PubMed ID: 20217938
[No Abstract] [Full Text] [Related]
8. Mortality among urban drug users and the impact of highly active antiretroviral therapy.
Celentano DD
Clin Infect Dis; 2005 Sep; 41(6):873-4. PubMed ID: 16107988
[No Abstract] [Full Text] [Related]
9. Initiating highly active antiretroviral therapy and continuity of HIV care: the impact of incarceration and prison release on adherence and HIV treatment outcomes.
Palepu A; Tyndall MW; Chan K; Wood E; Montaner JS; Hogg RS
Antivir Ther; 2004 Oct; 9(5):713-9. PubMed ID: 15535408
[TBL] [Abstract][Full Text] [Related]
10. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
Van Vaerenbergh K
Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
[TBL] [Abstract][Full Text] [Related]
11. Expanded access to highly active antiretroviral therapy: a potentially powerful strategy to curb the growth of the HIV epidemic.
Lima VD; Johnston K; Hogg RS; Levy AR; Harrigan PR; Anema A; Montaner JS
J Infect Dis; 2008 Jul; 198(1):59-67. PubMed ID: 18498241
[TBL] [Abstract][Full Text] [Related]
12. Universal access to HIV/AIDS treatment for injecting drug users: keeping the promise.
Ball AL
Int J Drug Policy; 2007 Aug; 18(4):241-5. PubMed ID: 17689371
[No Abstract] [Full Text] [Related]
13. HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy.
Steingrover R; Pogány K; Fernandez Garcia E; Jurriaans S; Brinkman K; Schuitemaker H; Miedema F; Lange JM; Prins JM
AIDS; 2008 Aug; 22(13):1583-8. PubMed ID: 18670217
[TBL] [Abstract][Full Text] [Related]
14. [Antiretroviral therapy in 2004].
Jablonowski H
MMW Fortschr Med; 2004 Apr; 146 Spec No 1():46-8, 50-1. PubMed ID: 15373049
[TBL] [Abstract][Full Text] [Related]
15. Highly active antiretroviral therapy for injection drug users: physician-recommended strategies for enhanced adherence.
Vassilev ZP; Hagan H
Antivir Ther; 2004 Jun; 9(3):461. PubMed ID: 15259910
[No Abstract] [Full Text] [Related]
16. Directly observed therapy programmes for anti-retroviral treatment amongst injection drug users in Vancouver: access, adherence and outcomes.
Tyndall MW; McNally M; Lai C; Zhang R; Wood E; Kerr T; Montaner JG
Int J Drug Policy; 2007 Aug; 18(4):281-7. PubMed ID: 17689376
[TBL] [Abstract][Full Text] [Related]
17. [How HIV treatment can be simplified. "Once daily" as starter therapy is effective].
Wepner U
MMW Fortschr Med; 2009 Apr; 151(18):80-1. PubMed ID: 19769085
[No Abstract] [Full Text] [Related]
18. Increase in sexual risk behavior associated with immunologic response to highly active antiretroviral therapy among HIV-infected injection drug users.
Tun W; Gange SJ; Vlahov D; Strathdee SA; Celentano DD
Clin Infect Dis; 2004 Apr; 38(8):1167-74. PubMed ID: 15095224
[TBL] [Abstract][Full Text] [Related]
19. Antiretroviral resistance among HIV-infected persons who have died in British Columbia, in the era of modern antiretroviral therapy.
Recsky MA; Brumme ZL; Chan KJ; Wynhoven B; Yip B; Dong WW; Heath KV; Montaner JS; Levy AR; Hogg RS; Harrigan PR
J Infect Dis; 2004 Jul; 190(2):285-92. PubMed ID: 15216463
[TBL] [Abstract][Full Text] [Related]
20. Psychosocial determinants of adherence to highly active antiretroviral therapy among injection drug users in Vancouver.
Kerr T; Palepu A; Barness G; Walsh J; Hogg R; Montaner J; Tyndall M; Wood E
Antivir Ther; 2004 Jun; 9(3):407-14. PubMed ID: 15259903
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
